Recombinant adeno-associated viruses (AAVs) have emerged as promising gene delivery
vehicles resulting in three US Food and Drug Administration (FDA) and one European …

This meeting was organized by The Transplantation Society with the assistance of an
unconditional education grant from CSL Behring. CSL Behring had no involvement in the …

Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in
humans,, and block liver transduction,–and vector readministration; thus, they represent a …

Background Donor-specific antibodies create an immunologic barrier to transplantation.
Current therapies to modify donor-specific antibodies are limited and ineffective in the most …

Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene
therapy owing to its minimal pathogenicity and ability to establish long-term gene expression …

Gene therapy is poised to revolutionize modern medicine, with seemingly unlimited potential
for treating and curing genetic disorders. For otherwise incurable indications, including most …

Preexisting humoral immunity to recombinant adeno-associated virus (AAV) vectors restricts
the treatable patient population and efficacy of human gene therapies. Approaches to clear …

Background. Highly HLA sensitized patients have limited access to life-saving kidney
transplantation because of a paucity of immunologically suitable donors. Imlifidase is a …

Objectives: The presence of a donor-specific positive crossmatch has been considered to be
a contraindication to kidney transplantation because of the risk of hyperacute rejection …

Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG-degrading enzyme of
Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single-center, open-label …